Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 29, 2017
- Revision received April 13, 2017
- Accepted April 19, 2017
- Published online May 27, 2017.
Copyright & Usage
Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
Author Information
- COURECHE KADERBHAI1,2,
- CORENTIN RICHARD2,3,
- JEAN DAVID FUMET1,2,
- ANNE AARNINK1,
- PASCAL FOUCHER4,
- BRUNO COUDERT1,
- LAURE FAVIER1,
- AURÉLIE LAGRANGE1,
- EMERIC LIMAGNE2,3,
- ROMAIN BOIDOT2,3 and
- FRANCOIS GHIRINGHELLI1,2,3⇑
- 1Department of medical oncology, Center GF Leclerc, Dijon, France
- 2Plateform transfer in biological Oncology, Dijon, France
- 3GIMI Genetic and Immunology Medical Institute, Dijon, France
- 4Department of Thoracic Oncology CHU, Dijon, France
- Correspondence to: Professor François Ghiringhelli, Centre Georges François Leclerc, Genetic and Immunology Medical Institute GIMI, 1 rue du professeur Marion, 21000 Dijon, France. Tel: +33 380393353, Fax: +33 380393434, e-mail: fghiringhelli{at}cgfl.fr
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
- Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer
- Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group